Allogene Therapeutics, Inc. of SOUTH SAN FRANCISCO, CA, a company, filed a Form D exempt-offering notice with the SEC on 2018-04-19. The offering totals $411.8M, of which $411.8M was reported sold. Industry: Biotechnology.
| Name | Role | Location |
|---|---|---|
| ROBERT M ABRAHAM | Director | SOUTH SAN FRANCISCO, CA |
| ARIE M BELLDEGRUN | Director | SOUTH SAN FRANCISCO, CA |
| DAVID M BONDERMAN | Director | SOUTH SAN FRANCISCO, CA |
| DAVID M CHANG | Director | SOUTH SAN FRANCISCO, CA |
| JOHN M DEYOUNG | Director | SOUTH SAN FRANCISCO, CA |
| FRANZ M HUMER | Director | SOUTH SAN FRANCISCO, CA |
| Joshua A Kazam | Director | San Mateo, CA |
| TODD M SISITSKY | Director | SOUTH SAN FRANCISCO, CA |
| OWEN M WITTE | Director | SOUTH SAN FRANCISCO, CA |
| Joshua A Kazam | Executive Officer | San Mateo, CA |
| David M Tanen | Executive Officer | New York, NY |